IBIO · iBio, Inc.
$1.46
+0.03 (+2.10%)
At close · Aug 17
Going-concern doubt
— cleared May 12, 2026
The latest filing states the doubt was alleviated.
“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 12, 2026
Market Cap
$71.04M
Shares
49.68M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$400K
+77.8%
FY2025
Net Income
-$18.38M
+26.2%
FY2025
Gross Margin
115.02%
+76.7pp
FY2022
Operating Margin
-4650.5%
+2742.4pp
FY2025
Diluted EPS
-$1.75
+73.1%
FY2025
Operating Cash Flow
-$15.3M
+17.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $300K | $400K | $225K | $0 | $1.88M | $2.37M | $1.64M | $2.02M | $444K | $394K | $948K | $1.85M | $205K | $1.01M | $1.28M | $520.08K | |
| — | — | — | — | $216K | $1.46M | $703K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $2.17M | $909K | $935K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | 115.02% | 38.34% | 57.08% | — | — | — | — | — | — | — | — | — | |
| $14.31M | $8.31M | $5.19M | $10.33M | $9.83M | $9.99M | $3.57M | $5.47M | $3.99M | $4.12M | $3.16M | $3.5M | $1.9M | $3.43M | $4.98M | $3.08M | |
| $14.95M | $10.69M | $11.67M | $19.02M | $21.75M | $22.03M | $11.37M | $12.33M | $10.69M | $10.55M | $7.69M | $5.02M | $3.89M | $4.24M | $5.62M | $7.09M | |
| $20K | $20K | $20K | $126K | $401K | $291K | $298K | $322K | $341K | $350K | $363K | $358K | $358K | $336K | $323K | $373K | |
| — | — | — | — | — | — | — | $179K | — | — | — | — | — | — | $329.71K | $376.81K | |
| $29.26M | $19M | $16.86M | $29.34M | $31.58M | $32.02M | $14.94M | $17.81M | $14.67M | $14.67M | $10.84M | $8.52M | $4.05M | $7.67M | $10.6M | $10.17M | |
| -$28.96M | -$18.6M | -$16.63M | -$29.34M | -$29.7M | -$31.11M | -$14M | -$15.79M | -$14.23M | -$14.27M | -$9.89M | -$6.67M | -$3.84M | -$6.67M | -$9.33M | -$9.65M | |
| — | -4650.5% | -7392.89% | — | -1576.27% | -1312.15% | -854.88% | -782.36% | -3204.28% | -3622.84% | -1043.57% | -360.13% | -1873.17% | -662.07% | -730.38% | -1856.25% | |
| — | — | — | — | — | — | — | -$15.61M | — | — | — | — | — | — | -$9M | -$9.28M | |
| $143K | $212K | $172K | $83K | $1.41M | $2.45M | $2.47M | $1.9M | $1.92M | $1.93M | $807K | $0 | $0 | $90K | $63K | $50.5K | |
| $1.5M | $437K | $363K | $213K | $177K | $140K | $15K | $75K | $15K | $39K | $22K | $9000 | $8000 | $9000 | $12K | $12.62K | |
| $1.35M | $225K | $1.19M | $32K | $184K | $7.9M | -$2.44M | -$1.81M | -$1.88M | -$1.87M | -$764K | $41K | $174K | $469K | $0 | -$2.49M | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$27.61M | -$18.38M | -$24.91M | -$65.01M | -$50.3M | -$23.21M | -$16.44M | -$17.59M | -$16.11M | -$14.53M | -$9.76M | -$6.63M | -$3.67M | -$6.2M | -$5.68M | -$12.14M | |
| — | -4594.25% | -11069.78% | — | -2670.01% | -978.79% | -1003.6% | -871.8% | -3627.25% | -3688.32% | -1029.96% | -357.91% | -1788.29% | -615.49% | -444.48% | -2334.73% | |
| — | — | — | — | -$1000 | -$6000 | -$5000 | -$4000 | -$3000 | -$1.61M | -$893K | $0 | — | — | — | — | |
| — | — | — | -$29.31M | -$29.6M | -$23.47M | -$38.26M | -$17.85M | -$16.37M | -$14.62M | -$9.76M | -$6.63M | -$3.67M | — | — | — | |
| USD/shares | — | -$1.75 | -$6.50 | -$106.19 | -$115.60 | -$60.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.75 | -$6.50 | -$106.19 | -$115.60 | -$60.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 10.5M | 3.83M | 612K | 436.05K | 391.25K | 125.59K | 37.85K | 21.26K | 17.82K | 161.95K | 142.99K | 125.94K | 98.76K | 79.012 | 61.94K |
| shares | — | 10.5M | 3.83M | 612K | 436.05K | 391.25K | 125.59K | 37.85K | 21.26K | 17.82K | 161.95K | 142.99K | 125.94K | 98.76K | 79.012 | 61.94K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.38×
EV/EBIT
—
Peer median 11.89×
P/E (TTM)
—
Peer median 9.25×
Peer medians compare against the 300 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Ibio Inc | $1,884,000 | $1,098,000 |
| Ibio Cdmo | $499,000 | $1,274,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Ibio Cdmo | -$20,496,000 | -$16,412,000 |
| Ibio Inc | -$29,194,000 | -$14,699,000 |
Operating Margin by Segment (%)
| Component | FY2022 | FY2021 |
|---|---|---|
| Ibio Inc | -1549.6% | -1338.7% |
| Ibio Cdmo | -4107.4% | -1288.2% |
Key facts
CIK
1420720
CUSIP
451033708
13F (30d)
59 filings
56 filers
Visit website
Investor relations